{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:22:12Z","timestamp":1790785332074,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:00:00Z","timestamp":1688947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:00:00Z","timestamp":1688947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s11897-023-00616-y","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T05:01:35Z","timestamp":1688965295000},"page":"350-357","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Natriuretic Peptides and Cardiac Troponins: Markers of Disease Progression and Risk in Light Chain Cardiac Amyloidosis"],"prefix":"10.1007","volume":"20","author":[{"given":"Isabel","family":"Wees","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas S.","family":"Hendren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurbakhash","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori R.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2400-3196","authenticated-orcid":false,"given":"Justin L.","family":"Grodin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,10]]},"reference":[{"key":"616_CR1","doi-asserted-by":"crossref","unstructured":"Fotiou D, Theodorakakou F, Kastritis E. Biomarkers in AL amyloidosis. Int J Mol Sci. 2021;22(20):10916.","DOI":"10.3390\/ijms222010916"},{"issue":"12","key":"616_CR2","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","volume":"68","author":"RH Falk","year":"2016","unstructured":"Falk RH, Alexander KM, Liao R, Dorbala S. AL (Light-Chain) Cardiac amyloidosis: a review of diagnosis and therapy. J Am Coll Cardiol. 2016;68(12):1323\u201341.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"616_CR3","doi-asserted-by":"publisher","first-page":"8552","DOI":"10.1038\/s41598-019-44912-x","volume":"9","author":"UA Tahir","year":"2019","unstructured":"Tahir UA, Doros G, Kim JS, Connors LH, Seldin DC, Sam F. Predictors of mortality in light chain cardiac amyloidosis with heart failure. Sci Rep. 2019;9(1):8552.","journal-title":"Sci Rep"},{"issue":"3","key":"616_CR4","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ejheart.2003.12.015","volume":"6","author":"C Hall","year":"2004","unstructured":"Hall C. Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail. 2004;6(3):257\u201360.","journal-title":"Eur J Heart Fail"},{"key":"616_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-2423(05)40001-3","volume":"40","author":"O Vuolteenaho","year":"2005","unstructured":"Vuolteenaho O, Ala-Kopsala M, Ruskoaho H. BNP as a biomarker in heart disease. Adv Clin Chem. 2005;40:1\u201336.","journal-title":"Adv Clin Chem"},{"issue":"5","key":"616_CR6","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1536\/ihj.19-043","volume":"60","author":"Y Kimishima","year":"2019","unstructured":"Kimishima Y, Yoshihisa A, Kiko T, Yokokawa T, Miyata-Tatsumi M, Misaka T, et al. Utility of B-type natriuretic peptide for detecting cardiac involvement in immunoglobulin amyloidosis. Int Heart J. 2019;60(5):1106\u201312.","journal-title":"Int Heart J"},{"issue":"6","key":"616_CR7","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/ejhf.1494","volume":"21","author":"C Mueller","year":"2019","unstructured":"Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JGF, Kozhuharov N, et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019;21(6):715\u201331.","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"616_CR8","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/ajh.23141","volume":"87","author":"G Palladini","year":"2012","unstructured":"Palladini G, Foli A, Milani P, Russo P, Albertini R, Lavatelli F, et al. Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. Am J Hematol. 2012;87(5):465\u201371.","journal-title":"Am J Hematol"},{"issue":"3","key":"616_CR9","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/bjh.16198","volume":"188","author":"B Lilleness","year":"2020","unstructured":"Lilleness B, Doros G, Ruberg FL, Sanchorawala V. Establishment of brain natriuretic peptide - based criteria for evaluating cardiac response to treatment in light chain (AL) amyloidosis. Br J Haematol. 2020;188(3):424\u20137.","journal-title":"Br J Haematol"},{"issue":"2","key":"616_CR10","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.cardiores.2005.10.001","volume":"69","author":"T Nishikimi","year":"2006","unstructured":"Nishikimi T, Maeda N, Matsuoka H. The role of natriuretic peptides in cardioprotection. Cardiovasc Res. 2006;69(2):318\u201328.","journal-title":"Cardiovasc Res"},{"issue":"19","key":"616_CR11","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1161\/01.CIR.0000068314.02595.B2","volume":"107","author":"G Palladini","year":"2003","unstructured":"Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation. 2003;107(19):2440\u20135.","journal-title":"Circulation"},{"issue":"10","key":"616_CR12","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1038\/leu.2016.191","volume":"30","author":"G Merlini","year":"2016","unstructured":"Merlini G, Lousada I, Ando Y, Dispenzieri A, Gertz MA, Grogan M, et al. Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis. Leukemia. 2016;30(10):1979\u201386.","journal-title":"Leukemia"},{"issue":"6","key":"616_CR13","doi-asserted-by":"publisher","first-page":"e009038","DOI":"10.1161\/CIRCHEARTFAILURE.121.009038","volume":"15","author":"MS Maurer","year":"2022","unstructured":"Maurer MS, Dunnmon P, Fontana M, Quarta CC, Prasad K, Witteles RM, et al. Proposed cardiac end points for clinical trials in immunoglobulin light chain amyloidosis: report from the Amyloidosis Forum Cardiac Working Group. Circ Heart Fail. 2022;15(6):e009038.","journal-title":"Circ Heart Fail"},{"issue":"10","key":"616_CR14","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1136\/jcp.2003.015420","volume":"57","author":"S Sharma","year":"2004","unstructured":"Sharma S, Jackson PG, Makan J. Cardiac troponins. J Clin Pathol. 2004;57(10):1025\u20136.","journal-title":"J Clin Pathol"},{"issue":"18","key":"616_CR15","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","volume":"22","author":"A Dispenzieri","year":"2004","unstructured":"Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751\u20137.","journal-title":"J Clin Oncol"},{"issue":"5","key":"616_CR16","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1136\/heartjnl-2013-304957","volume":"100","author":"A Dispenzieri","year":"2014","unstructured":"Dispenzieri A, Gertz MA, Kumar SK, Lacy MQ, Kyle RA, Saenger AK, et al. High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis. Heart. 2014;100(5):383\u20138.","journal-title":"Heart"},{"issue":"14","key":"616_CR17","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1182\/blood-2010-02-267708","volume":"116","author":"AV Kristen","year":"2010","unstructured":"Kristen AV, Giannitsis E, Lehrke S, Hegenbart U, Konstandin M, Lindenmaier D, et al. Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay. Blood. 2010;116(14):2455\u201361.","journal-title":"Blood"},{"issue":"5","key":"616_CR18","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1093\/ehjci\/jez180","volume":"21","author":"M Nicol","year":"2020","unstructured":"Nicol M, Baudet M, Brun S, Harel S, Royer B, Vignon M, et al. Diagnostic score of cardiac involvement in AL amyloidosis. Eur Heart J Cardiovasc Imaging. 2020;21(5):542\u20138.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"10","key":"616_CR19","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.acvd.2013.06.051","volume":"106","author":"D Mohty","year":"2013","unstructured":"Mohty D, Damy T, Cosnay P, Echahidi N, Casset-Senon D, Virot P, et al. Cardiac amyloidosis: updates in diagnosis and management. Arch Cardiovasc Dis. 2013;106(10):528\u201340.","journal-title":"Arch Cardiovasc Dis"},{"issue":"5","key":"616_CR20","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.jaccao.2020.10.011","volume":"2","author":"JE Liu","year":"2020","unstructured":"Liu JE, Barac A, Thavendiranathan P, Scherrer-Crosbie M. Strain Imaging in Cardio-Oncology. JACC Cardio Oncol. 2020;2(5):677\u201389.","journal-title":"JACC Cardio Oncol"},{"issue":"8","key":"616_CR21","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.amjcard.2012.05.061","volume":"110","author":"T Apridonidze","year":"2012","unstructured":"Apridonidze T, Steingart RM, Comenzo RL, Hoffman J, Goldsmith Y, Bella JN, et al. Clinical and echocardiographic correlates of elevated troponin in amyloid light-chain cardiac amyloidosis. Am J Cardiol. 2012;110(8):1180\u20134.","journal-title":"Am J Cardiol"},{"key":"616_CR22","doi-asserted-by":"publisher","first-page":"626414","DOI":"10.3389\/fcvm.2021.626414","volume":"8","author":"AM Agha","year":"2021","unstructured":"Agha AM, Palaskas N, Patel AR, DeCara J, Parwani P, Iliescu C, et al. Cardiac magnetic resonance predicting outcomes among patients at risk for cardiac AL amyloidosis. Front Cardiovasc Med. 2021;8:626414.","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"616_CR23","doi-asserted-by":"publisher","first-page":"6516","DOI":"10.1038\/s41467-021-26845-0","volume":"12","author":"P Kazman","year":"2021","unstructured":"Kazman P, Absmeier RM, Engelhardt H, Buchner J. Dissection of the amyloid formation pathway in AL amyloidosis. Nat Commun. 2021;12(1):6516.","journal-title":"Nat Commun"},{"issue":"9","key":"616_CR24","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","volume":"30","author":"S Kumar","year":"2012","unstructured":"Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989\u201395.","journal-title":"J Clin Oncol"},{"issue":"36","key":"616_CR25","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","volume":"30","author":"G Palladini","year":"2012","unstructured":"Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30(36):4541\u20139.","journal-title":"J Clin Oncol"},{"key":"616_CR26","doi-asserted-by":"crossref","unstructured":"Czy\u017cewska E, Wi\u015bniewska A, Waszczuk-Gajda A, Ciepiela O. The role of light kappa and lambda chains in heart function assessment in patients with AL amyloidosis. J Clin Med. 2021;10(6):1274.","DOI":"10.3390\/jcm10061274"},{"issue":"3","key":"616_CR27","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1182\/blood-2016-02-702696","volume":"128","author":"E Kastritis","year":"2016","unstructured":"Kastritis E, Papassotiriou I, Terpos E, Roussou M, Gavriatopoulou M, Komitopoulou A, et al. Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis. Blood. 2016;128(3):405\u20139.","journal-title":"Blood."},{"issue":"10","key":"616_CR28","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1002\/ajh.25576","volume":"94","author":"A Pudusseri","year":"2019","unstructured":"Pudusseri A, Sanchorawala V, Sloan JM, Bever KM, Doros G, Kataria S, et al. Prevalence and prognostic value of D-dimer elevation in patients with AL amyloidosis. Am J Hematol. 2019;94(10):1098\u2013103.","journal-title":"Am J Hematol"},{"key":"616_CR29","doi-asserted-by":"crossref","unstructured":"Abdelaziz Mohamed I, Gadeau AP, Hasan A, Abdulrahman N, Mraiche F. Osteopontin: a promising therapeutic target in cardiac fibrosis. Cells. 2019;8(12):1558.","DOI":"10.3390\/cells8121558"},{"issue":"1","key":"616_CR30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1161\/CIRCHEARTFAILURE.107.746172","volume":"1","author":"M Rosenberg","year":"2008","unstructured":"Rosenberg M, Zugck C, Nelles M, Juenger C, Frank D, Remppis A, et al. Osteopontin, a new prognostic biomarker in patients with chronic heart failure. Circ Heart Fail. 2008;1(1):43\u20139.","journal-title":"Circ Heart Fail"},{"issue":"4","key":"616_CR31","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/00005792-197507000-00001","volume":"54","author":"RA Kyle","year":"1975","unstructured":"Kyle RA, Bayrd ED. Amyloidosis: review of 236 cases. Medicine. 1975;54(4):271\u201399.","journal-title":"Medicine"},{"issue":"7","key":"616_CR32","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1002\/ajh.25819","volume":"95","author":"MA Gertz","year":"2020","unstructured":"Gertz MA. Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment. Am J Hematol. 2020;95(7):848\u201360.","journal-title":"Am J Hematol"},{"issue":"5","key":"616_CR33","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41408-021-00486-4","volume":"11","author":"R Al Hamed","year":"2021","unstructured":"Al Hamed R, Bazarbachi AH, Bazarbachi A, Malard F, Harousseau JL, Mohty M. Comprehensive review of AL amyloidosis: some practical recommendations. Blood Cancer J. 2021;11(5):97.","journal-title":"Blood Cancer J"},{"issue":"8","key":"616_CR34","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1182\/blood-2016-04-710822","volume":"128","author":"V Sanchorawala","year":"2016","unstructured":"Sanchorawala V, Shelton AC, Lo S, Varga C, Sloan JM, Seldin DC. Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial. Blood. 2016;128(8):1059\u201362.","journal-title":"Blood"},{"issue":"5","key":"616_CR35","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/bjh.16096","volume":"187","author":"E Muchtar","year":"2019","unstructured":"Muchtar E, Gertz MA, Lacy MQ, Go RS, Buadi FK, Dingli D, et al. Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. Br J Haematol. 2019;187(5):588\u201394.","journal-title":"Br J Haematol"},{"issue":"4","key":"616_CR36","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/bmt.2012.170","volume":"48","author":"MA Gertz","year":"2013","unstructured":"Gertz MA, Lacy MQ, Dispenzieri A, Kumar SK, Dingli D, Leung N, et al. Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transplant. 2013;48(4):557\u201361.","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"616_CR37","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.jaccao.2022.08.011","volume":"4","author":"MC Minnema","year":"2022","unstructured":"Minnema MC, Dispenzieri A, Merlini G, Comenzo RL, Kastritis E, Wechalekar AD, et al. Outcomes by cardiac stage in patients with newly diagnosed AL amyloidosis: phase 3 ANDROMEDA trial. JACC Cardio Oncol. 2022;4(4):474\u201387.","journal-title":"JACC Cardio Oncol"},{"issue":"10","key":"616_CR38","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1002\/ajh.21822","volume":"85","author":"A Dispenzieri","year":"2010","unstructured":"Dispenzieri A, Dingli D, Kumar SK, Rajkumar SV, Lacy MQ, Hayman S, et al. Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. Am J Hematol. 2010;85(10):757\u20139.","journal-title":"Am J Hematol"},{"issue":"25","key":"616_CR39","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1182\/blood.2020009039","volume":"138","author":"CV Edwards","year":"2021","unstructured":"Edwards CV, Rao N, Bhutani D, Mapara M, Radhakrishnan J, Shames S, et al. Phase 1a\/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis. Blood. 2021;138(25):2632\u201341.","journal-title":"Blood"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-023-00616-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11897-023-00616-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-023-00616-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T04:13:20Z","timestamp":1697775200000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11897-023-00616-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,10]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["616"],"URL":"https:\/\/doi.org\/10.1007\/s11897-023-00616-y","relation":{},"ISSN":["1546-9530","1546-9549"],"issn-type":[{"value":"1546-9530","type":"print"},{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,10]]},"assertion":[{"value":"21 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JLG: consulting: Pfizer, Eidos\/BridgeBio, Alnlyam, Intellia, Sarepta, and AstraZeneca; grant support: Pfizer 67656485, Eidos\/BridgeBio, Texas Health Resources Clinical Scholarship, and NHLBI R01 HL160892-01A1. GK: consulting\/honoraria: BMS, Janssen, Sanofi, Arcellx, Kedrion, Pfizer; research funding: BMS, Janssen, and Abbvie.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}